How Does Neupogen Work?
Neupogen (filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the bone marrow to produce neutrophils, white blood cells key to fighting infections. It binds to G-CSF receptors on hematopoietic progenitor cells, promoting their proliferation and differentiation into neutrophils.[1]
Does It Effectively Treat Neutropenia?
Yes, clinical trials show Neupogen raises neutrophil counts in patients with chemotherapy-induced neutropenia, reducing infection risk and hospitalization time. In a pivotal study of 423 patients post-chemotherapy, median time to neutrophil recovery was 1.6 days with Neupogen versus 3.8 days without (p<0.001).[2] FDA approval in 1991 was based on such data demonstrating efficacy in non-myeloid malignancies.
What Conditions Is It Used For?
- Chemotherapy-induced neutropenia.
- Neutropenia from bone marrow transplants.
- Severe chronic neutropenia (Kostmann's syndrome).
- Neutropenia in HIV patients on antivirals.
It shortens neutropenia duration by 2-3 days on average across indications.[1][2]
Common Side Effects and Risks
Most patients experience bone pain (up to 30%), but serious risks include acute respiratory distress syndrome, splenic rupture (rare, <1%), and allergic reactions. Long-term use may increase myelodysplastic syndrome risk in predisposed patients. Monitor absolute neutrophil count (ANC) to avoid overshoot.[1]
How Does It Compare to Neulasta?
Neulasta (pegfilgrastim), a longer-acting pegylated version from the same maker (Amgen), requires one dose per chemo cycle versus daily Neupogen shots. Both raise ANC similarly, but Neulasta cuts injection frequency.[3] Neupogen generics (e.g., Zarxio, Nivestym) match efficacy at lower cost.
When Does the Original Patent Expire?
Neupogen's key composition patent (US 4,761,361) expired in 2015, enabling biosimilars like Zarxio (2015 approval). Remaining formulation patents expire by 2025-2030; check DrugPatentWatch.com for updates on litigation and exclusivity.[4]
[1]: Neupogen Prescribing Information (FDA)
[2]: NEJM 1991 Study on Filgrastim
[3]: Neulasta Prescribing Information (FDA)
[4]: DrugPatentWatch.com - Neupogen Patents